Core Insights - BrainsWay Ltd. reported record quarterly revenue of $12.6 million in Q2 2025, marking a 26% increase compared to Q2 2024 [1] - The company raised its full-year 2025 revenue guidance to between $50 million and $52 million, up from the previous range of $49 million to $51 million [4] - Remaining performance obligations increased by 25% year-over-year to $62 million, indicating strong future revenue visibility [1][4] Financial Performance - Operating profit for Q2 2025 totaled $0.6 million, consistent with the prior year [5] - Adjusted EBITDA rose 16% to $1.5 million in Q2 2025, compared to $1.3 million in Q2 2024 [5] - Net profit surged 233% to $2.0 million in Q2 2025, up from $0.6 million in Q2 2024 [5] Operational Highlights - The company shipped a net total of 88 Deep TMS™ systems in Q2 2025, a 35% increase from the same period last year, bringing the total installed base to 1,522 systems [5] - Approximately 70% of recent customer engagements are structured as multi-year lease agreements, contributing to stable revenue streams [5] - The company is actively pursuing minority equity investments in high-performing mental health providers to enhance its strategic initiatives [7] Guidance and Future Outlook - The company expects operating income for full-year 2025 to be between 4% and 5%, with Adjusted EBITDA projected at 12% to 13% [4] - BrainsWay's management expressed confidence in the momentum across its core market and the successful execution of its growth strategy [4][6]

Core Insights - BrainsWay Ltd. will report its first quarter 2025 financial results and operational highlights on May 13, 2025, before the U.S. market opens [1] - A conference call and webcast will be held at 8:30 AM Eastern Time on the same day to discuss the results and business operations [1][2] Company Overview - BrainsWay is a leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [3] - The company has obtained three FDA-cleared indications for its TMS technology, which include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [3] - Founded in 2003, BrainsWay operates in Israel and the U.S. and is focused on increasing global awareness and access to Deep TMS [3]